Celltrion's STEQEYMA® Introduced to Costco Member Prescription Program

Celltrion's STEQEYMA®: A New Hope for Patients Amid Rising Drug Costs

In a significant move towards improving healthcare access, Celltrion, Inc. has officially introduced its biosimilar STEQEYMA® (ustekinumab-stba) as part of the Costco Member Prescription Program. This development is aimed at offering a more affordable option for patients suffering from inflammatory conditions treated by the reference product, STELARA® (ustekinumab).

Expanding Accessibility to Essential Treatments

Celltrion’s Vice President of Market Access, Francine Galante, stated, "We are focused on improving affordability and access to a widely used, high-cost treatment for a variety of inflammatory conditions". With this addition, Celltrion aims to alleviate the financial burden faced by many patients who require effective treatment options.

Launched on March 12, 2025, STEQEYMA promises to make strides in the market not just as another medication but as a necessary solution to tackle high prescription costs. Francine Galante highlighted that STEQEYMA's inclusion in the Costco Member Prescription Program, alongside adalimumab-aaty added earlier, signals a commitment to minimizing financial barriers within the healthcare system.

Treatment Indications and Administration

STEQEYMA is indicated for a broad range of inflammatory conditions, including plaque psoriasis (PsO), psoriatic arthritis (PsA), Crohn’s disease (CD), and ulcerative colitis (UC). It is available in subcutaneous injection and intravenous infusion formats to cater to various patient preferences and clinical needs. This versatility is anticipated to enhance treatment strategies across different patient demographics, including both adults and pediatric populations.

Costco Health Solutions has made it easier for its members by allowing access to lower prices on STEQEYMA and other medications through their pharmacies. This discount card program empowers eligible Costco members and their dependents to secure essential drugs at more budget-friendly rates. As Tom Nusbickel, Chief Commercial Officer at Celltrion USA, states, "By partnering with Costco Health Solutions once again, we help even more Americans lower the price of their prescriptions."

A Response to Rising Prescription Drug Prices

With STELARA frequently ranked as one of the most expensive prescription drugs on the market, the introduction of STEQEYMA presents a substantial opportunity to bring cost-effective alternatives to the forefront. Patients covered under self-funded employer plans or those who are uninsured and opting to pay cash can look forward to obtaining STEQEYMA from Costco Specialty Pharmacies starting April 1, 2025.

Safety Information and Precautions

While STEQEYMA carries significant benefits, it is essential to understand the associated safety precautions. The medication is contraindicated in patients exhibiting hypersensitivity to ustekinumab products or any components of the drug. Additionally, patients are cautioned against starting the treatment during existing infections and must be evaluated for tuberculosis (TB) before beginning therapy. A thorough discussion of potential side effects, including serious infections and hypersensitivity reactions, should occur between healthcare providers and patients prior to prescribing the medication.

About Celltrion and Their Commitment

Celltrion has positioned itself as a leader in biosimilars, having been the pioneer in launching the world’s first monoclonal antibody biosimilar. The company demonstrates an ongoing commitment to improving global health through innovative therapeutics that target serious diseases, with specific attention directed towards immunology, oncology, and rheumatology. As the U.S. subsidiary, Celltrion USA emphasizes the extension of access to quality medicines, reflecting their dedication to enhancing patient care.

In conclusion, the addition of STEQEYMA to Costco's prescription program heralds a new chapter in biopharmaceutical affordability and accessibility, promising to deliver relief to countless patients grappling with the high cost of essential treatments.